ABSTRACT
Systemic steroids are important in the treatment for various diseases, including allergic, immunologic, malignant and dermatologic conditions long-term use of glucocorticodes may result in serious side effects such as osteoporosis, hyperlipidemia, cardiovascular disease, immunosuppression, adrenal suppression, psychiatric and cognitive disorders. In this article, it was aimed to inform dermatologists about the side effects of systemic steroids and management of these side effects.
References
1Poetker DM, Reh DD. A comprehensive review of the adverse effects ofsystemic corticosteroids. Otolaryngol Clin North Am 2010; 43: 753-768.
2Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-1124.
3Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119: 1198-1208.
4Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-426.
5Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986; 31: 102-110.
6Long WF. A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom Physiol Opt 1977; 54: 248-252.
7Stanbury R, Graham E. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998; 82: 704-708.
8Pappas DA, Hooper MM, Kremer JM, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2015; 67: 1671-1678.
9Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
10van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166: 1016-1020.
11White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary. J Am Acad Dermatol 1994; 30: 768-773.
12Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 1264-1267.
13Svenson KL, Lithell H, Hällgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987; 147: 1912-1916.
14Saag KG, Furst DE. Major side effects of systemic glucocorticoids, Up to date. https://www.uptodate.com/contents/major-side-effects-of-systemic-glucocorticoids?search=major-side-effects-ofsystemic-%20glucocorticoids&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
15Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985; 76: 234-242.
16Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81: 1361-1367.
17Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009; 1179: 41-55.
18Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47: 1396-1402.
19Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30: 135-139.
20Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012; 169: 491-497.
21van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787.
22Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet 1967; 2: 856-859.
23Ortega E, Rodriguez C, Strand LJ, Segre E. Effects of cloprednol and other corticosteroids on hypothalamic-pituitary-adrenal axis function. J Int Med Res 1976; 4: 326-337.
24Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-1567.
25Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid -induced side effects: a comprehensive review: infectious complications and vaccination recommendations. J Am Acad Dermatol 2017; 76: 191-198.
26Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9: 30.
27Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017; 76: 1-9.
28Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-1526.
29Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab 1998; 83: 2350-2354.
30Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid -induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects. J Am Acad Dermatol 2017; 76: 11-16.
